To Top

Search By Topic

Discovery

49 Articles available
Discovery

A New Landscape: M&A in the Discovery & Research Sector

PAP-Q1-18-NI-002
Biologics

Fully Supporting Customer Needs for Biologics Development and Manufacturing

PAP-Q1-18-CL-016
Innovation

Single-Pill, HIV-1 Combination Therapy Approved

PAO-M11-17-NI-050
Discovery

Boehringer Ingelheim and HitGen Enter Drug Discovery Collaboration

PAO-M11-17-NI-049
FDA Approval

Advanced Follicular Lymphoma Treatment Approved

PAO-M11-17-NI-048
Gene Editing

Excision BioTherapeutics Licenses UC Berkeley CRISPR Systems

PAO-M11-17-NI-046
Non-Opioid

SiteOne Therapeutics Garners US Department of Defense Award

PAO-M11-17-NI-036
Acquisition

Mallinckrodt Expands Pipeline with Ocera Therapeutics Buy

PAO-M11-17-NI-020
CRISPR

CRISPR Technology Could Enable New Treatments for Resistant Fungal Infections

PAO-M11-17-NI-006
Genetics

Unlocking the Relationship Between Genetics and Disease

PAO-M10-17-NI-044
Drug Discovery

Forge Therapeutics and Evotec Expand Their Partnership

PAO-M10-17-NI-041
Research

Don’t Be Scared: New Insight into How the Brain Learns Fear

PAO-M10-17-NI-040
Information Technology

Fighting Opioid Abuse, Axial Healthcare Rolls Out New IT-based Care Platform

PAO-M10-17-NI-034
Clinical Trials

Greenovation Biotech GmbH Announces Completion Of Its Phase I Safety Study For moss-aGal Targeting Fabry Disease

PR-M10-17-NI-005
Vaccine

Merck, J&J Receive BARDA Funding for Ebola Vaccine Development

PAO-M10-17-NI-019
Discovery

NIH Funds Novel Small Molecule Approach to Interrupt Alzheimer’s Dementia

PAO-M10-17-NI-003
Strategy

Icagen on the Road to BIO: Early-Stage Planning for End-Stage Success

Kenneth F. Wertman Ph.D., Senior Vice President, Icagen. View more about Icagen on the Road to BIO.

PTV-M06-17-CL-012
Discovery

First On-Label Abuse-Deterrent Opioid Approved

PAO-M04-17-NI-026
Discovery

TRULANCE Gets Veteran to Pilot IBS Therapy Launch

PAO-M04-17-NI-024
FDA

Novartis CAR-T Cell Therapy Receives Breakthrough Therapy Designation

PAO-M04-17-NI-025
Discovery

Mestoblast’s Stem-cell Therapy for Heart Failure Reaches Phase III

PAO-M04-17-NI-013
Discovery

Fusion Antibodies, MAB Discovery Team to Speed Antibody Development

PAO-M04-17-NI-018
Discovery

23andMe Personal Genome Service Gets FDA Nod

PAO-M04-17-NI-015
Discovery

Inovio Ebola DNA Vaccine Demonstrates Robust Immune Response

PAO-M04-17-NI-012
Discovery

Disease in a Dish: Creating Human Tissues In Vitro

Paul August, Ph.D, Vice President Biology, Icagen

PTV-M11-16-AP-014
FDA

FDA Approves Breakthrough Cancer Therapy

PAO-M04-17-NI-003
Discovery

Aptuit in Bacteria Resistance Collaboration

PAO-M03-17-NI-011
Discovery

Big Data: A Big Challenge

PAP-Q1-17-NO-001
Discovery

New Ventures in the Microbiome

PAP-Q1-17-TT-001
Outsourcing

Integrated Innovation: Fostering the New Growth in Pharma

PAP-Q1-17-CL-003
Discovery

Move Toward Cell-Based Manufacturing Signals Opening in Vaccine Market

MCP-M02-17-NI-002
Discovery

Tunable Microgels to Advance Cell Therapy

PAO-M12-16-NI-002
CDMO

Beginning Your Digital Transformation

CPP-M11-16-NI-001
API

The Search for Practical and Economical Catalysts

PTO-M10-16-NI-001
Biologics

INNOVATION: Creating Solutions for Healthcare’s Ambitious Agenda

PAP-Q04-16-FA-001
CDMO

A Foundation of Innovation

PAP-Q04-16-IN-001
API

New Strategies Required to Meet Changing Needs in the Analytical Services Market

PAP-Q04-16-CL-010
CDMO

Transforming the Pharmaceutical Industry Pipeline with In Silico Approaches

PAP-Q04-16-CL-011
CDMO

Patient-Centric Drug Development: Designing Medicines to Succeed

PAP-Q03-16-CL-004
API

Integrating Drug Discovery and Development to Improve Efficiency and Candidate Success

PAP-Q02-16-CL-005
Biologics

The Buzz Around Oncology — Update On Biologics Approvals

LSL-M11-15-NI-001
Outsourcing

Identifying Segmentation Within the Pharmaceutical Outsourcing Market

POP-M02-15-NI-001
Outsourcing

The Continued Evolution of the Sponsor-CRO Relationship

LSL-M08-14-NI-001
Outsourcing

An Update on the Buzz Around Oncology

LSL-M07-14-NI-002
Outsourcing

Can CROs Help Reduce the Expense of Clinical Trials?

LSL-M05-14-NI-001
Outsourcing

The Evolving Dynamic Of The Sponsor-CRO Relationship

CIO-M12-12-NI-001